SI-BONE (NASDAQ:SIBN) Shares Up 3.9% – Should You Buy?

SI-BONE, Inc. (NASDAQ:SIBN) rose 3.9% on Friday . The stock traded as high as $13.11 and last traded at $12.93. Approximately 195,026 shares were traded during trading, a decline of 50% from the average daily volume of 390,482 shares. The stock had previously closed at $12.44.

Wall Street Analyst Weigh In

SIBN has been the topic of several research reports. Truist Financial boosted their price target on shares of SI-BONE from $16.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday. Morgan Stanley decreased their target price on shares of SI-BONE from $21.00 to $19.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $19.00 price target on shares of SI-BONE in a research report on Wednesday. Six research analysts have rated the stock with a buy rating, According to MarketBeat, SI-BONE has a consensus rating of “Buy” and a consensus price target of $23.00.

SI-BONE Trading Up 3.9 %

The stock’s 50-day simple moving average is $14.03 and its two-hundred day simple moving average is $14.29. The company has a debt-to-equity ratio of 0.22, a quick ratio of 8.12 and a current ratio of 8.25.

Insider Activity at SI-BONE

In related news, insider Anthony J. Recupero sold 2,087 shares of the business’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $14.17, for a total transaction of $29,572.79. Following the completion of the transaction, the insider now owns 236,717 shares in the company, valued at $3,354,279.89. The trade was a 0.87 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last ninety days, insiders have sold 7,147 shares of company stock worth $102,194. Insiders own 3.90% of the company’s stock.

Institutional Trading of SI-BONE

Several institutional investors and hedge funds have recently made changes to their positions in SIBN. Geode Capital Management LLC increased its stake in SI-BONE by 3.4% in the 3rd quarter. Geode Capital Management LLC now owns 924,044 shares of the company’s stock worth $12,921,000 after buying an additional 30,005 shares during the period. Barclays PLC increased its position in shares of SI-BONE by 190.8% during the third quarter. Barclays PLC now owns 96,623 shares of the company’s stock worth $1,350,000 after acquiring an additional 63,402 shares during the period. Y Intercept Hong Kong Ltd bought a new stake in shares of SI-BONE during the third quarter valued at approximately $448,000. Pier Capital LLC raised its stake in shares of SI-BONE by 23.6% during the third quarter. Pier Capital LLC now owns 465,898 shares of the company’s stock valued at $6,513,000 after acquiring an additional 88,897 shares in the last quarter. Finally, Jane Street Group LLC boosted its holdings in shares of SI-BONE by 29.0% in the third quarter. Jane Street Group LLC now owns 77,359 shares of the company’s stock valued at $1,081,000 after purchasing an additional 17,410 shares during the period. 98.11% of the stock is currently owned by institutional investors.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.